Merck Shares Jump After Positive Phase 3 NSCLC Readout for Sac-TMT Combination
Merck shares climbed roughly 4.7% in morning trading after interim Phase 3 data from the OptiTROP-Lung05 trial showed that sacituzumab tirumotecan (sac-TMT), developed with Kelun Biotech and given with Keytruda, outperformed Keytruda alone in non-small cell lung cancer. The result, together with additional oncology data slated for ASCO, a supportiv…